Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from KALA BIO ( (KALA) ).
On December 26, 2025, Kala Bio, Inc. paid $2 million to Oxford Finance, LLC under a previously disclosed Loan Settlement Agreement linked to prior events of default under a 2021 Loan and Security Agreement involving the company and its subsidiary Combangio, Inc. With this payment, Kala Bio’s approximately $10.6 million aggregate liability to Oxford was fully settled and released, eliminating its obligations under both the settlement and the original loan, which strengthens the company’s balance sheet and resolves a significant debt-related overhang for stakeholders.
The most recent analyst rating on (KALA) stock is a Sell with a $0.55 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
The score is primarily weighed down by weak financial performance (minimal revenue, large losses, negative equity, and significant cash burn) and bearish technical signals (below major moving averages with negative MACD). Valuation provides little support due to unprofitability (negative P/E) and no dividend yield.
To see Spark’s full report on KALA stock, click here.
More about KALA BIO
Kala Bio, Inc. operates in the biotechnology/pharmaceutical sector, focusing on developing therapies through its subsidiary Combangio, Inc., and has historically used debt financing arrangements, such as a Loan and Security Agreement with Oxford Finance, LLC, to support its operations.
Average Trading Volume: 7,553,697
Technical Sentiment Signal: Sell
Current Market Cap: $12.19M
For detailed information about KALA stock, go to TipRanks’ Stock Analysis page.